Tissue plasminogen activator and plasminogen activator inhibitor 1 in obese and lean patients with polycystic ovary syndrome

Gynecol Endocrinol. 2010 Oct;26(10):743-8. doi: 10.3109/09513590.2010.487592.

Abstract

Objective: Disturbances in the fibrinolytic system are predictors of future cardiovascular events. The aim of this study was to compare plasminogen activator inhibitor 1 (PAI-1) activity and tissue plasminogen activator (tPA) mass concentration between patients with polycystic ovary syndrome (PCOS) and control subjects.

Design: One hundred thirty-five patients with PCOS (lean and obese) and 81 healthy controls were recruited for the study. Blood samples for PAI-1 activity and tPA mass were collected together with anthropometric measures.

Results: Obese patients with PCOS displayed increased tPA mass concentration in comparison with controls (p <0.05), and this finding was consistent regardless of whether patients displayed signs of hyperandrogenism or not. When hyperandrogenism was introduced as a prerequisite for the PCOS diagnosis, obese patients with PCOS displayed increased PAI-1 activity as well, p <0.05. Lean patients with PCOS did not differ in terms of PAI-1 activity or tPA mass concentration in comparison to controls.

Conclusion: Obese women with PCOS have impaired fibrinolysis, in particular if they also display objective biochemical markers of hyperandrogenism.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Case-Control Studies
  • Female
  • Fibrinolysis*
  • Humans
  • Hyperandrogenism / blood
  • Hyperandrogenism / physiopathology
  • Obesity / blood*
  • Obesity / complications
  • Obesity / physiopathology
  • Plasminogen Activator Inhibitor 1 / blood*
  • Polycystic Ovary Syndrome / blood*
  • Polycystic Ovary Syndrome / complications
  • Polycystic Ovary Syndrome / physiopathology
  • Regression Analysis
  • Tissue Plasminogen Activator / blood*

Substances

  • Plasminogen Activator Inhibitor 1
  • Tissue Plasminogen Activator